Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

This study is testing pembrolizumab (an immunotherapy drug) as a non-surgical treatment for cervical intraepithelial neoplasia (CIN) grade 2 or 3 — precancerous changes in the cervix that, if untreated, can develop into cervical cancer. The goal is to see if the immune system can be activated to clear these abnormal cells without surgery. **You may be eligible if...** - You are a woman, at least 21 years old - You have active (not yet surgically removed) CIN grade 2, CIN grade 3, or carcinoma in situ confirmed by biopsy - You are not pregnant or breastfeeding - You are using adequate contraception if you could become pregnant **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your lesion has already been removed surgically - You have invasive cervical cancer (this study is for pre-cancerous lesions only) - You have had prior immunotherapy or have active autoimmune conditions Talk to your doctor to see if this trial is right for you.